Eli Lilly and Company

Azevan Pharmaceuticals, Inc.

Robert F Bruns, Jr

Donald R Gehlert

J Jeffry Howbert

William H Lunn

Gary A Koppel

David C Hunden

Jeffrey J Skelton

Bruce Anthony Dressman

Stephen W Kaldor

Mitchell I Steinberg

John Robert Rizzo

Paul Leslie Ornstein

Dennis Michael Zimmerman

Philip Arthur Hipskind

Marvin J Miller

Thomas Charles Britton

Robin D Cooper

Hamideh Zarrinmayeh

Karen Lynn Lobb

Ned D Heindel

Edward C R Smith

James Arthur Nixon

Robin D G Cooper

Christophe D G Guillon

Buddy Eugene Cantrell

James Jeffry Howbert

Michael O Chaney

William H W Lunn

Anne Marie Nunes

Shifang Lu

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin Vreceptor 

[object Object]

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin Vreceptor.

Non-peptidyl vasopressin V1A antagonists

Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

Non-peptidyl vasopressin V1a antagonists

This invention provides a series of substituted benzimidazoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted benzimidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.

Benzimidzolyl neuropeptide Y receptor antagonists

This invention provides a series of substituted indoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides the novel substituted indoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these substituted indoles.

Indolyl neuropeptide Y receptor antagonists

This invention provides methods and 2-(azetidin-2-on-1-yl)acetic acid derivatives for the antagonism of the vasopressin V,receptor.

This invention relates to a combinatorial process for synthesizing a library of azetidinone peptide-like compounds. The compounds are synthesized as mixtures from a common azetidinone intermediate. The compounds are biologically active as inhibitors of the Vasopressin (V1a) receptor.

Combinatorial process for synthesizing azetidinone analogs

This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.

Heterocyclic neuropeptide Y receptor antagonists

A method of inhibiting the physiological disorder anxiety associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

Method of treating anxiety by inhibiting physiological conditions

A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

Methods of treating depression by inhibiting physiological conditions

A method of inhibiting obesity, a physiological disorder associated with an excess of neuropeptide Y, or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

Methods of treating obesity by inhibiting physiological conditions

A method of inhibiting a physiological condition associated with an excess of bradykinin comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

Methods of inhibiting physiological conditions associated with an excess

This invention provides methods of treating a physiological disorder associated with an excess of bradykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.

Growing community of inventors

Carmel, IN, United States of America

Robert F Bruns, Jr